The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
Status:
Terminated
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
Based on data regarding the effect of colchicine on the inflammasome NLP3 and microtubule
formation and associations thereof with the pathogenetic cycle of SARS-COV-2, the question
arises whether colchicine, administered in a relatively low dose, could potentially have an
effect the patients' clinical course by limiting the myocardial necrosis and pneumonia
development in the context of COVID-19. If present, this effect would be attributed to its
potential to inhibit inflammasome and (less probably) to the process of SARS-CoV-2
endocytosis in myocardial and endothelial respiratory cells.